Validation of the EASL 2017 HBV Clinical Practice Guidelines criteria for switching patients long-term treated with Tenofovir Difumarate to Entecavir or Tenofovir Alafenamide in a real-life setting

Background and aims: The 2017 EASL HBV CPG recommend switching TDF treated patients to TAF (NUC naïve or experienced) or ETV (only NUC naïve) if they have one of the following risk factors: (1) age >60 years, (2) bone disease [history of fragility fracture, osteoporosis, chronic use of steroids or medications that worsen BMD], and (3) renal alterations [eGFR <60 mL/min, albuminuria >30 mg/24 h or moderate dipstick proteinuria, low serum phosphate (<2.5 mg/dL), or hemodialysis]. We want to estimate the number of patients who could benefit from this switch in a cohort of TDF-treated patients.